Allergan's Botox Holds Its Own In Migraine, Despite CGRP Competition

In the third quarter, generics of dry eye drug Restasis did not emerge as expected and Botox enjoyed double digit sales for therapeutic indications in the US, despite the entry of new competition in migraine treatment.